CA-CEPTON-TECHNOLOGIES
19.8.2021 15:02:13 CEST | Business Wire | Press release
Leading lidar solutions provider Cepton received two recognitions at Tech.AD Europe this year for its innovations, adding to the company’s growing portfolio of award-winning lidar solutions across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005247/en/
Tech.AD is a leading technical conference in Europe focused on technologies for autonomous driving (AD) and the advancements of artificial intelligence (AI) technology in the automotive industry. The annual Tech.AD Europe Award exclusively honors "extraordinary projects in the automotive industry and celebrates exceptional solutions & innovations." Awards are announced after submissions are rated by a jury of some of the top subject matter experts in Europe.
Cepton was recognized in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies for its Nova lidar . Second place award-winner in this category, Nova is a pathbreaking miniature, wide field of view (FOV) lidar sensor for near-range perception in advanced driver assistance systems (ADAS), autonomous vehicle (AV) and autonomous ground vehicle (AGV) applications. Nova provides an attractive combination of performance, compactness, FOV coverage and affordability and enables a range of use cases such as high-accuracy blind spot detection, small object detection, automated park assist and free space estimation around the vehicle.
Another award was given to a Cepton lidar-enabled smart cities project - Traffic Monitoring as Source of Training Data for Autonomous Vehicles - by Cepton partner ALP.Lab , which won the top prize in the category of Most Advanced Real-Life Testing & Simulation Techniques in Autonomous Driving . Deployed in the City of Graz, the ALP.Lab project utilizes Cepton’s Helius ® Smart Lidar System and Vista® -P lidars to enable advanced, real-time, 3D traffic and pedestrian analytics. According to ALP.Lab, “the enormous amount of time and expense involved in collecting training data for ADAS/AD development can be dramatically reduced by this new and sustainable lidar perception based technique focused on specific roads and environments likely to generate the most diverse and difficult driving environments.”
The Tech.AD Europe awards represent a continuation of past recognitions of Cepton’s lidar innovations. Previously, Cepton received awards for its lidar solutions across multiple applications, including the AUVSI XCELLENCE in Innovation Award in 2019 for the Sora™ lidar, the Security Today New Product of the Year Award in 2019 in the Perimeter Protection category for the first generation of Helius® known as Vista-Edge, the Autonomous Vehicle Technology ACES Award in 2020 jointly with Cepton partner Dataspeed for the Vista® -P lidar, and the CES Innovation Award in 2020 in two categories – Smart Cities and Tech for a Better World – for the Helius® Smart Lidar system, that also includes our Vista® -P lidars.
Dr. Jun Pei, CEO of Cepton, said: “The awards at Tech.AD Europe were not only based on jury selection, but also based on the voting of all of the conference attendees representing leading automotive OEMs, autonomous vehicle companies, Tier 1 suppliers, and other R&D organizations worldwide. We are grateful for this recognition and what it represents for the continued innovation we are bringing to market using our MMT® lidar technology. Increasingly, the role of Cepton lidars in the future of mobility is becoming clear worldwide and we are pleased to work with global partners such as ALP.Lab in advancing safety and autonomy.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in North America, Germany, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom